Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia
NCT ID: NCT00873249
Last Updated: 2010-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
339 participants
OBSERVATIONAL
2009-04-30
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia
NCT00406718
MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications
NCT01953237
Improving Antipsychotic Adherence Among Patients With Serious Mental Illness
NCT00057135
Using Short Message Service as a Means of Clinical Engagement in Early Psychosis
NCT04379349
Study of Mental Care in Spain
NCT00824031
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With a diagnosis of schizophrenia (DSM-IV TR criteria)
* Stabilized out-patients
* Under oral antipsychotic monotherapy
Exclusion Criteria
* Suicide risk
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Alicante, Alicante, Spain
Research Site
Almería, Almeria, Spain
Research Site
Barcelona, Barcelona, Spain
Research Site
Berga, Barcelona, Spain
Research Site
Sabadell, Barcelona, Spain
Research Site
Burgos, Burgos, Spain
Research Site
Santander, Cantabria, Spain
Research Site
Córdoba, Cordoba, Spain
Research Site
Granada, Granada, Spain
Research Site
León, Leon, Spain
Research Site
Lleida, Lerida, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Málaga, Malaga, Spain
Research Site
Murcia, Murcia, Spain
Research Site
Pamplona, Navarre, Spain
Research Site
Oviedo, Oviedo, Spain
Research Site
Palma Mallorca, Palma Mallorca, Spain
Research Site
Salamanca, Salamanca, Spain
Research Site
Seville, Sevilla, Spain
Research Site
Tarragona, Tarragona, Spain
Research Site
Toledo, Toledo, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Valladolid, Valladolid, Spain
Research Site
Zamora, Zamora, Spain
Research Site
Calatayud, Zaragoza, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-NES-DUM-2007/3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.